Clinical Trial Update: Neoadjuvant Chemoradiation With Nal-IRI and Capecitabine Guided by UGT1A1 Status in Patients With Rectal Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial of neoadjuvant chemoradiation with Nal-IRI and capecitabine guided by UGT1A1 status in rectal cancer; currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rectal Cancer

Drugs mentioned

• Capecitabine (capecitabine)
• Nal-IRI (liposomal irinotecan) (liposomal irinotecan)

Snippet

Sponsor: Hebei Medical University Fourth Hospital | Conditions: Rectal Cancer | Phase 2 | Status: RECRUITING